137 Prospective quality of life measurement in SOCCAR no disadvantage for patients receiving concurrent vs sequential treatment with 55Gy/20f and cisplatinum/vinorelbine

137 Prospective quality of life measurement in SOCCAR no disadvantage for patients receiving concurrent vs sequential treatment with 55Gy/20f and cisplatinum/vinorelbine J. Maguire1 *, R. McMenemin2, N. O’Rourke3, C. Peedell4, M. Snee5, S. McNee3, V. Kelly1, I. Khan6, R. Slade6. 1Liverpool Heart Heart and Chest Hospital, Liverpool, UK, 2Northern Centre for Cancer Care, Newcastle, UK, 3Beatson Oncology Centre, Glasgow, UK, 4James Cook University Hospital, Middlesborough, UK, 5St James’s Institute of Oncology, Leeds, UK, 6UCL Cancer Trials Centre, London, UK